NO20091274L - Farmasoytiske faste doseformer inneholdende forbindelser som er mikro-innesluttet i ioniske vann-uloselige polymere - Google Patents

Farmasoytiske faste doseformer inneholdende forbindelser som er mikro-innesluttet i ioniske vann-uloselige polymere

Info

Publication number
NO20091274L
NO20091274L NO20091274A NO20091274A NO20091274L NO 20091274 L NO20091274 L NO 20091274L NO 20091274 A NO20091274 A NO 20091274A NO 20091274 A NO20091274 A NO 20091274A NO 20091274 L NO20091274 L NO 20091274L
Authority
NO
Norway
Prior art keywords
dosage forms
ionic water
solid dosage
entrapped
micro
Prior art date
Application number
NO20091274A
Other languages
English (en)
Inventor
Antonio A Albano
Navnit Hargovindas Shah
Wantanee Phuapradit
Zhongshui Yu
Lin Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20091274L publication Critical patent/NO20091274L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer nye farmasøytiske faste doseformer for oral administrering omfattende en terapeutisk effektiv mengde av en ustabil krystallinsk form eller en amorf form av en terapeutisk effektiv forbindelse mikro-innleiret i en ionisk vann-uoppløselig polymer. De terapeutiske effektive forbindelser, som har en tendens til å stivne, er mikro-innleiret i en ionisk vann-uoppløselig polymermatriks for å gi en doseform som har rask, reproduserbar og fullstendig oppløsningsprofil. Disse nye faste farmasøytiske doseformer er anvendelige i behandlingen eller kontroll av flere sykdommer.
NO20091274A 2006-10-13 2009-03-27 Farmasoytiske faste doseformer inneholdende forbindelser som er mikro-innesluttet i ioniske vann-uloselige polymere NO20091274L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85185206P 2006-10-13 2006-10-13
US95440107P 2007-08-07 2007-08-07
PCT/EP2007/060542 WO2008043701A1 (en) 2006-10-13 2007-10-04 Pharmaceutical solid dosage forms comprising compounds micro-embedded in ionic water-insoluble polymers

Publications (1)

Publication Number Publication Date
NO20091274L true NO20091274L (no) 2009-05-28

Family

ID=38857877

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091274A NO20091274L (no) 2006-10-13 2009-03-27 Farmasoytiske faste doseformer inneholdende forbindelser som er mikro-innesluttet i ioniske vann-uloselige polymere

Country Status (16)

Country Link
US (1) US20080107725A1 (no)
EP (1) EP2079447A1 (no)
JP (1) JP2010505901A (no)
KR (1) KR20090053858A (no)
AR (1) AR063259A1 (no)
AU (1) AU2007306402A1 (no)
BR (1) BRPI0719880A2 (no)
CA (1) CA2665604A1 (no)
CL (1) CL2007002921A1 (no)
IL (1) IL197871A0 (no)
MX (1) MX2009003516A (no)
NO (1) NO20091274L (no)
PE (1) PE20081461A1 (no)
RU (1) RU2009117711A (no)
TW (1) TW200824709A (no)
WO (1) WO2008043701A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6215238B2 (ja) * 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
EP3228307A1 (en) * 2016-04-05 2017-10-11 Sandoz Ag Solid dispersion comprising opioid antagonists
EP3556354B1 (en) * 2016-12-15 2025-05-21 Hua Medicine (Shanghai) Ltd. Oral preparation of glucokinase activator and preparation method therefor
AU2019278015B2 (en) * 2018-05-31 2024-10-03 Hua Medicine (Shanghai) Ltd. Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
DE19515972A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung
CA2277220A1 (en) * 1997-01-10 1998-07-16 Abbott Laboratories Tablet for the controlled release of active agents
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
ATE400252T1 (de) * 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU5227001A (en) * 2000-05-03 2001-11-12 Hoffmann La Roche Hydantoin-containing glucokinase activators
JP5178982B2 (ja) * 2000-05-18 2013-04-10 セリックス， インコーポレイテッド 経口投薬形態における、毒性コアの非毒性領域中へのカプセル化
PL370989A1 (en) * 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
EP1496052B1 (en) * 2002-03-26 2009-08-05 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
AU2003263024A1 (en) * 2002-04-23 2003-11-10 Christopher Mcconville Process of forming and modifying particles and compositions produced thereby
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
CA2540104A1 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles comprising inclusion complexes

Also Published As

Publication number Publication date
US20080107725A1 (en) 2008-05-08
EP2079447A1 (en) 2009-07-22
WO2008043701A1 (en) 2008-04-17
IL197871A0 (en) 2009-12-24
CL2007002921A1 (es) 2008-05-30
CA2665604A1 (en) 2008-04-17
TW200824709A (en) 2008-06-16
AR063259A1 (es) 2009-01-14
PE20081461A1 (es) 2008-10-18
KR20090053858A (ko) 2009-05-27
BRPI0719880A2 (pt) 2014-06-10
JP2010505901A (ja) 2010-02-25
MX2009003516A (es) 2009-04-14
RU2009117711A (ru) 2010-11-20
AU2007306402A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
NO20091274L (no) Farmasoytiske faste doseformer inneholdende forbindelser som er mikro-innesluttet i ioniske vann-uloselige polymere
CY1126116T1 (el) Φαρμακευτικες συνθεσεις αποτελουμενες απο νιλοτινιμπη
WO2008021113A3 (en) Transdermal methods and systems for treating alzheimer's disease
NO20092723L (no) Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer
NO20084712L (no) Nye farmasoytiske forbindelser
NO20083836L (no) N-hydroksyakrylamidforbindelser
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
UA111579C2 (uk) ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
MY158019A (en) Controlled activation ingestible identifier
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
JO2858B1 (en) Pharmaceutical dosage images
UA106878C2 (uk) Фармацевтична композиція, що містить 4-[3-(4-циклопропанкарбонілпіперазин-1-карбоніл)-4-фторбензил]-2н-фталазин-1-он або його сіль, або сольват, у твердій дисперсії з матричним полімером коповідоном
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
WO2008087186A3 (en) Peptides for use in the treatment of obesity
WO2008144061A3 (en) Novel combinations comprising a phosphodiesterase-5 inhibitor and their use
EA200970081A1 (ru) Соединения, обладающие потенциирующим действием в отношении активности этионамида, и их применения
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
WO2007089934A3 (en) Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers
PT103884A (pt) Composições de libertação prolongada e métodos para a sua preparação

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application